Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QV4A
|
|||
| Former ID |
DIB008562
|
|||
| Drug Name |
NI-0501
|
|||
| Synonyms |
Anti-IFN gamma antibody, NovImmune/Merck Serono; Anti-IFN gamma antibody, NovImmune/Serono; Anti-interferon gamma antibody, NovImmune/Merck Serono; Anti-interferon gamma antibody, NovImmune/Serono
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23; ICD-10: D76.1] | Phase 2 | [2] | ||
| Company |
NovImmune SA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01818492) A Study to Investigate the Safety and Efficacy of an Anti-IFN mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.